Alnylam Pharmaceuticalsincis A Biopharmaceutical Company Based In Cambridgemassachusettsfounded In 2002It Is A Leader In Rna Interferencernaitherapeuticsutilizing This Technology To Silence Genes Associated With Diseasesthe Company Was Established By Prominent Scientists In The Field And Has Contributed Significantly To Rnai Researchwith Over 250 Peer Reviewed Publications Alnylam Develops Rnai Therapeutics Targeting Specific Genes Linked To Various Diseasesits Product Portfolio Includes Onpattropatisiran Givlaarigivosiran And Oxlumolumasiran All Of Which Have Received Fda Approval For Treating Rare Genetic Conditionsthe Company Has A Robust Clinical Pipeline With 15 Ongoing Programs Across Multiple Therapeutic Areasincluding Genetic Medicines And Neurodegenerative Diseasesalnylam Operates Globallysupporting Its Innovative Therapies And Maintaining A Strong Commercial Presence
United States
